Forget Stem Cell Tourism: Stem Cell Clinics in the US Are Plentiful

The Domestic Stem Cell Clinic Boom

A major 2021 analysis identified 1,480 US businesses operating 2,754 clinics that marketed purported stem cell treatments directly to consumers. That represented a dramatic expansion from earlier surveys of the industry. California, Texas, and Florida emerged as major centers, although clinics were found throughout the country. In other words, the modern stem cell marketplace looks less like a remote medical-tourism industry and more like a nationwide retail network.

The typical patient may encounter a clinic through a social media advertisement, search-engine result, seminar, podcast, chiropractor’s office, pain-management practice, or glowing testimonial. The presentation can feel reassuringly familiar: a polished website, people in white coats, scientific illustrations, and phrases such as “regenerative,” “natural healing,” “cellular repair,” and “cutting-edge medicine.”

Unfortunately, scientific vocabulary is not the same thing as scientific evidence. A photograph of cells under a microscope does not automatically turn an injection into an approved therapy. Neither does a tasteful blue logo featuring a DNA helix. The helix has been asked to perform far too much unpaid marketing work.

What Stem Cell Treatments Are Actually FDA-Approved?

Stem cells are real, medically important, and central to legitimate research. Blood-forming stem cells have been used for decades in carefully controlled transplantation procedures for certain cancers, blood disorders, immune-system diseases, and loss of bone marrow function. These treatments are performed by specialized medical teams and are very different from a cash-pay injection marketed for knee pain or general wellness.

The US Food and Drug Administration states that the stem cell products it has approved consist of blood-forming cells derived from umbilical cord blood and are approved for disorders affecting blood production. They are not approved as general treatments for orthopedic pain, neurological diseases, blindness, autism, chronic fatigue, heart disease, or lung disease. The agency also states that no exosome products are currently FDA-approved.

“Registered With the FDA” Is Not the Same as “FDA-Approved”

One of the most confusing marketing claims is that a clinic, facility, laboratory, or product is “FDA-registered.” Registration may mean that an establishment submitted certain information to the agency. It does not mean the FDA reviewed the treatment and determined that it was safe and effective for the condition being advertised.

The same warning applies to ClinicalTrials.gov. A study’s appearance in the database does not automatically mean that the treatment is legitimate, FDA-authorized, scientifically sound, or endorsed by the federal government. The FDA has specifically warned consumers that clinics may use registration or trial listings to create a misleading appearance of official approval.

Why Are So Many Clinics Able to Operate?

Human cells and tissues are regulated according to how they are collected, processed, manipulated, and used. Certain minimally manipulated tissues used for the same basic function they performed in the donor may qualify for a less burdensome regulatory pathway. Products that are more extensively processed, obtained from another person, or used for a substantially different biological purpose generally face stricter requirements, including premarket review.

This framework is scientifically and legally complicated, which creates room for disagreement, creative interpretation, and aggressive marketing. A clinic may claim that its procedure falls under a tissue exception or involves the patient’s own cells. However, using cells from a patient’s fat or bone marrow does not automatically establish that every processing method and proposed use complies with federal law.

State Laws Can Add Another Layer

Florida illustrates how the landscape continues to evolve. A 2025 state statute permits qualifying physicians to perform certain non-FDA-approved stem cell therapies related to orthopedics, wound care, or pain management, subject to sourcing, advertising, consent, accreditation, and manufacturing requirements. The required notice must tell patients that the therapy has not been approved by the FDA.

That distinction matters. A treatment may be offered under a state framework while still lacking FDA approval for safety and effectiveness. “Available,” “permitted under specified conditions,” and “proven to work” are three separate concepts. Marketing brochures occasionally place them in a blender and serve the resulting smoothie as certainty.

The Risks Are Not Merely Theoretical

Any injection or infusion carries some risk. Cell-based products add concerns involving contamination, immune reactions, inappropriate cell growth, movement of cells to unintended areas, neurological complications, tumors, and failure to receive effective standard care. The FDA has listed blindness, bacterial infections, life-threatening bloodstream infections, inflammatory reactions, neurological events, and tumor formation among the safety concerns associated with illegally marketed regenerative products.

Blindness After an Experimental Eye Procedure

A widely cited report in The New England Journal of Medicine described three patients who experienced severe vision loss after receiving injections of fat-derived cells into both eyes for age-related macular degeneration. The procedures were offered by a clinic associated with a study listing, but the existence of that listing did not mean the intervention had been proven safe or effective.

Hospitalizations From Contaminated Cord-Blood Products

The Centers for Disease Control and Prevention investigated infections linked to non-FDA-approved umbilical cord blood-derived products administered for pain and orthopedic conditions. Twelve patients in Texas, Florida, and Arizona developed infections, including bloodstream infections, joint infections, and epidural abscesses. All were hospitalized. Testing found bacterial contamination in unopened product vials.

These cases demonstrate why manufacturing standards, sterility testing, product identity, dosage, delivery method, and long-term follow-up matter. Living cells are not magic dust. They are biologically active materials capable of behaving in complex and sometimes dangerous ways.

Marketing Claims Can Travel Faster Than Evidence

The Federal Trade Commission has repeatedly acted against companies accused of deceptively advertising stem cell products. In January 2025, federal court orders banned the founders of the Stem Cell Institute of America and related businesses from marketing stem cell therapy. The defendants were ordered to pay more than $5.1 million in penalties and refunds under Georgia law. According to the FTC, affiliated clinics had used seminars and promotional materials to attract largely elderly or disabled consumers, sometimes charging up to $5,000 per injection.

FDA enforcement has continued as well. Warning letters issued in 2025 described umbilical cord, amniotic fluid, and exosome products marketed for conditions including neuropathy, inflammation, pain, autoimmune disease, neurodegenerative disorders, diabetes, autism, and spinal cord injury. The agency characterized the cited products as unapproved drugs and unlicensed biological products.

These actions do not prove that every regenerative medicine clinic is dishonest. They do show that consumers should not assume a clinic’s continued operation establishes federal approval, clinical effectiveness, or regulatory compliance.

Common Red Flags at a US Stem Cell Clinic

The International Society for Stem Cell Research advises patients to look for reliable scientific evidence, qualified specialists, independent oversight, meaningful informed consent, and a clear explanation of risks. Several warning signs deserve particular attention.

• One cell product supposedly treats unrelated diseases. A clinic claiming that the same injection treats arthritis, Parkinson’s disease, autism, kidney disease, and hair loss is making an extraordinary claim requiring extraordinary evidence.
• Testimonials replace controlled studies. Personal stories cannot separate true treatment effects from placebo effects, natural recovery, temporary symptom fluctuations, or simultaneous treatments.
• The clinic promises no risk. No invasive medical procedure is risk-free, particularly one involving living biological material.
• Payment is required immediately. High-pressure discounts, financing plans, or “today only” medical offers belong at a mattress outlet, not in a careful clinical decision.
• The cell source is vague. Patients should know whether cells come from their own fat or marrow, donated cord tissue, placenta, amniotic material, or another source.
• The doctor is not a specialist in the condition. Expertise in injections does not automatically equal expertise in multiple sclerosis, autism, macular degeneration, or complex orthopedic disease.
• There is no long-term follow-up plan. Cell-related complications may not appear immediately.

How to Evaluate a Proposed Treatment

Start by requesting the exact name of the product and the exact cells it contains. Ask whether the treatment is FDA-approved for your specific condition. When the answer is no, ask whether it is being administered under an active Investigational New Drug application and request the IND number.

Patients should also request published, peer-reviewed studies involving the same product, dose, delivery method, and medical condition. A laboratory experiment in mice is not proof that a knee injection works in humans. A study involving blood cancer is not evidence for treating back pain. Biology is annoyingly specific that way.

Ask who reviewed the protocol, who will treat complications, whether the clinic carries appropriate insurance, and who pays for emergency care. Obtain an independent second opinion from a board-certified physician who specializes in the underlying disease and has no financial relationship with the clinic.

For orthopedic conditions, the American Academy of Orthopaedic Surgeons says evidence supporting stem cell treatments remains limited or mixed. It recommends discussing the evidence, regulatory status, risks, and out-of-pocket costs with a qualified doctor.

Stem Cell Science Still Deserves Optimism

Skepticism about commercial clinics should not be confused with skepticism about stem cell research. Researchers are studying cell-based approaches for neurological disease, heart damage, diabetes, spinal cord injuries, eye conditions, immune disorders, and tissue repair. Some experimental treatments may eventually become standard medicine.

However, promising science becomes dependable medicine through staged laboratory work, manufacturing controls, independent review, carefully designed clinical trials, comparison groups, adverse-event monitoring, and transparent publication of negative as well as positive results. The ISSCR emphasizes that commercial use is unjustified for the many conditions where evidence of safety and effectiveness remains insufficient.

The uncomfortable truth is that medical progress is slower than marketing. A website can be launched on Friday. Establishing long-term safety may take years.

Conclusion: The New Stem Cell Tourism May Be a Drive Across Town

Stem cell tourism has not disappeared, but it no longer adequately describes the problem. US patients can now encounter unproven regenerative treatments without leaving their stateor sometimes their neighborhood. The domestic market includes legitimate research centers, specialized transplant programs, compliant medical practices, questionable operators, and businesses occupying contested regulatory territory.

The safest response is neither automatic enthusiasm nor blanket rejection. It is disciplined verification. Patients should identify the product, confirm its FDA status, examine condition-specific evidence, investigate the physician’s credentials, request independent oversight information, review costs and complications, and seek an unbiased second opinion.

Hope is essential when living with pain or serious disease. It should be protected, not monetized through vague promises. A reputable clinician will welcome careful questions. A salesperson wearing a lab coat may suddenly discover another appointment.

A Composite Patient Experience: From Online Hope to Informed Choice

The following scenario is a composite illustration based on marketing patterns, patient-safety guidance, and enforcement cases. It does not describe one identifiable patient.

Imagine a 66-year-old woman named Carol who has lived with knee osteoarthritis for several years. Physical therapy helped, but not enough. Anti-inflammatory medication irritates her stomach, and her orthopedic surgeon has mentioned that knee replacement may eventually become appropriate. Carol is not ready for major surgery, which is understandable. Few people hear “joint replacement” and immediately reach for a party hat.

One evening, she sees a social media advertisement for a nearby regenerative medicine seminar. The advertisement features smiling older adults hiking on a mountain trail. The clinic promises a nonsurgical approach using “youthful cellular signaling” and “advanced stem cell technology.” It does not explicitly guarantee cartilage regrowth, but the wording strongly encourages that interpretation.

At the seminar, a persuasive speaker explains that conventional medicine manages symptoms while regenerative medicine addresses the underlying problem. Several attendees share testimonials about walking farther, sleeping better, and avoiding surgery. Carol is offered a free consultation and is told that appointment space is limited.

During the consultation, a staff member recommends injections in both knees. The proposed treatment costs several thousand dollars and is not covered by insurance. Financing is available. When Carol asks whether it is FDA-approved, she is told that the laboratory is FDA-registered and that the treatment uses ethically donated birth tissue. The answer sounds official but does not address her actual question.

Carol takes the consent form home rather than signing immediately. Her primary care physician helps her identify the product and confirms that it is not FDA-approved for osteoarthritis. An independent orthopedic specialist reviews the clinic’s evidence and finds that the cited studies involve different products, small patient groups, inconsistent preparation methods, or outcomes that do not prove cartilage regeneration.

Carol then contacts the clinic with specific questions. What cells are alive in the final product? What is the dose? Is there an active IND? Has the exact product been tested in a randomized trial for knee osteoarthritis? Who pays if she develops an infection? How are adverse events reported? The clinic provides broad assurances but few precise answers.

She decides not to proceed. Instead, she develops a revised plan with her medical team involving targeted exercise, weight management, an assistive brace, periodic injections with better-established evidence, and clear criteria for reconsidering surgery. Her pain does not magically disappear, but her decision becomes grounded in realistic benefits, known risks, and transparent follow-up.

Another patient might review similar information and choose enrollment in a properly regulated clinical trial. The important experience is not that every experimental option must be refused. It is that the decision should occur without artificial urgency, misleading regulatory language, or testimonials masquerading as proof.

Patients often approach stem cell clinics after years of discomfort, disability, failed treatments, and disappointing medical appointments. They deserve empathy rather than ridicule. The responsibility for evidence belongs to the people selling the intervention, not to the patient who desperately wants it to work. Asking for proof is not negativity. It is informed consent doing its job.